The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
The potential deal would shift Neumann's already diminished voting power to the Japanese conglomerate, according to the Journal.Technologyread more
Hunter's vows to forgo any foreign work follow a slew of unsubstantiated attacks by President Donald Trump accusing him of corruption.Politicsread more
Fisher was initially defiant amid the backlash in an interview with Bloomberg, in which he said he had "given a lot of talks, a lot of times, in a lot of places and said stuff...Personal Financeread more
Airlines continue to delay when they plan to have the planes back again with no sign from regulators on when the planes will be approved again.Airlinesread more
Turkey's invasion of northeastern Syria began Wednesday after Trump ordered U.S. troops to pull back from the area.Politicsread more
While Warren's ad about Facebook isn't true, the company's own policy allows politicians to make such false claims in paid advertising.Politicsread more
Typhoon Hagibis made landfall south of Tokyo on Saturday evening. By Sunday around 376,000 homes were left without electricity, and 14,000 without running water across Japan....Weather & Natural Disastersread more
SpaceX and Boeing are each in the final stages of developing the spacecraft needed for the U.S. to once again fly astronauts.Investing in Spaceread more
Bryn Mawr's Jeffrey Mills believes the market needs more time to break out of its slump.Trading Nationread more
Shortly before he took office last year, President Donald Trump accused the pharmaceutical industry of "getting away with murder." As a candidate in 2016, he backed the idea of the government negotiating directly with drugmakers to lower Medicare drug prices.
The proposal, which broke with most Republicans, became one of Trump's most popular plans among Democrats in Congress. But when the president unveiled a sweeping platform Friday to reduce drug prices, it appeared not to include the Medicare negotiation plan.
During his remarks Friday, Trump said he wanted to develop "new tools to negotiate for lower prices" in Medicare Part D plans. The government wants to develop "incentives" to encourage companies to keep prices low, he said.
However, he did not specifically call for the direct price negotiation he described on the campaign trail.
Democrats, ahead of Trump's speech and after it, slammed the president for what they called abandoning a key campaign promise. The theme will likely play heavily in Democratic midterm messaging, as the party tries to gain seats in Congress partly by arguing the GOP has not done enough to help American consumers.
Amid Trump's remarks Friday, veteran Rep. Elijah Cummings, D-Md., said the president "is abandoning his promise" to allow direct negotiation to lower drug prices. He and his Democratic colleagues are also arguing the president's pledge to keep pharmaceutical companies in check rings hollow because the businesses received a massive tax benefit under the GOP tax overhaul passed in December.
As news emerged Thursday that Trump may not push for direct negotiations, Democrats accused him of abandoning his campaign priorities. Senate Minority Leader Chuck Schumer said candidate Trump "spoke like a populist who wanted to work in a bipartisan way."
"He talked the talk, but he has failed, at least so far, to walk the walk," the New York Democrat told reporters.
Sen. Bernie Sanders, a Vermont independent who caucuses with Democrats and a leading voice on the left, said if Trump is "serious about lowering drug prices," he would take action such as telling "the Republican leadership to support the Medicare price negotiation act." Sen. Dick Durbin, D-Ill., the chamber's second-ranking Democrat, argued earlier Friday that Trump is "breaking his promise" to bring down drug prices.
A White House official responded to the Democratic criticism by arguing the party's platform to reduce drug prices would hurt competition and innovation. The official contended that Democratic goals would not lower drug prices but instead hurt patients.